Executive Summary

Between 2025 and 2035 the Electronic Gastroscope Market is projected to expand from 31,250 USD Million to 67,466.4 USD Million, a CAGR of 8.0%.

Gastric cancer screening programs across Asia-Pacific and rising upper gastrointestinal endoscopy volumes are increasing procedure counts, while the EU Medical Device Regulation tightens approval requirements for diagnostic gastroscopy equipment.

North America led with a 34.36% share in 2025, ahead of Asia Pacific at 30.24% and Europe at 27.06%. Diagnostic applications hold the largest revenue base, while therapeutic use is expanding fastest.

MDR recertification costs for legacy devices in Europe constrain smaller manufacturers, alongside reimbursement variability in emerging markets. Competition across the Electronic Gastroscope Market remains fragmented, spanning regional and multinational device makers.

Key Takeaways

• From USD 31,250.00 Million in 2025, the market reaches USD 67,466.41 Million by 2035 at 8.0% a year.
• Diagnostic is the largest application category.
• On end use, the leading category is Hospitals.
• The largest region is North America, at 34.4% in 2025.
• The report profiles 13 suppliers across a fragmented field.

Market Definition and Scope

The Electronic Gastroscope Market comprises flexible, rigid and video gastroscopes built on optical, digital and wireless imaging technology, used for diagnostic, therapeutic, surgical and screening procedures across the esophagus, stomach and duodenum. End users span hospitals, ambulatory surgical centers and specialty gastroenterology clinics serving adult, pediatric and geriatric patients.

Colonoscopes, bronchoscopes and other lower-gastrointestinal or respiratory endoscopy systems sit outside this boundary, as do general-purpose laparoscopic surgical instruments not configured for upper gastrointestinal visualization.

Growth Drivers and Restraints

Reimbursement policy is shifting upper GI endoscopy toward ambulatory settings

CMS’s Calendar Year 2026 Hospital Outpatient and Ambulatory Surgical Center final rule, issued 21 November 2025 and effective 1 January 2026, added 560 procedures to the ASC Covered Procedures List, assigning them the CPT and HCPCS codes that set ASC payment, and opened a three-year phase-out of the Inpatient Only list running through CY2028, with ASC payment rates up 2.6%. Specialty clinics and ambulatory surgical centers, the fastest-growing end-use settings, absorb most of the resulting shift toward compact, video-based gastroscope systems billed under the new codes.

EU and US data rules are raising compliance costs for digital gastroscope platforms

The European Commission’s Medical Device Regulation extends conformity and post-market surveillance requirements to diagnostic endoscopy equipment, including electronic gastroscopes, and ties image-management software to the same data-protection standard GDPR sets for patient records. Regulation (EU) 2025/327, establishing the European Health Data Space, entered into force 26 March 2025 and brings medical imaging studies into its secondary-use scope from March 2031. US-bound platforms carry a parallel burden: hospital IT departments require HIPAA-compliant storage, and where a gastroscope generates or signs diagnostic records electronically, 21 CFR Part 11 validation before deployment. Both regimes push demand toward digital, EHR-integrated instruments built to a compliance specification rather than a lab prototype.

Regulatory recognition of AI-assisted image interpretation is opening a path for computer-aided detection in endoscopy

South Korea’s AI Framework Act and Enforcement Decree, effective 22 January 2026, classify diagnostic AI as “high-impact,” giving hospitals a defined compliance route for computer-aided detection modules inside video gastroscopes. In the United States, comparable modules clear FDA review through the 510(k) or De Novo pathway depending on novelty, with pivotal validation studies typically registered on ClinicalTrials.gov ahead of submission. The precedent extends further: the World Health Organization’s 11 June 2025 policy update doubled endorsed computer-aided detection products for imaging-based screening from four to eight, establishing WHO endorsement as a market-access gate for AI-based diagnostic software.

MDR recertification is raising the cost floor for legacy gastroscope lines

The European Commission’s Medical Device Regulation requires existing fiber-optic and rigid gastroscope lines to undergo renewed conformity assessment and post-market clinical follow-up before CE marks can be retained, and national HTA bodies increasingly ask for the same follow-up data before adding a recertified model to a reimbursement list. Smaller manufacturers without dedicated regulatory-affairs teams absorb the largest share of this cost, often withdrawing older instrument variants rather than resubmitting technical files. India’s CDSCO has moved in the same direction, tightening import registration for endoscopic devices, which concentrates the fragmented competitive base around companies able to fund recertification across multiple regulatory regimes at once.

Layered AI compliance duties are slowing deployment of smart endoscopy platforms

In South Korea, the AI Framework Act imposes operator-level risk-assessment, documentation and human-oversight duties on top of existing MFDS device approval, so a gastroscope platform with AI-based detection already cleared for sale still requires a second compliance layer before hospitals can put it into routine use. Procurement teams in hospitals and specialty clinics, already managing device-level regulatory files, treat this additional documentation burden as a reason to delay adoption of AI-integrated systems in favor of existing video gastroscope inventory.

Market Trends

Digital and wireless imaging is displacing fiber-optic gastroscope platforms

Digital technology is the fastest-growing gastroscope category by imaging platform, even as optical fiber-bundle systems retain the largest installed base. CMOS and CCD video sensors resolve mucosal detail that a fiberoptic eyepiece cannot, aiding detection of Barrett’s esophagus and gastric lesions. Most video gastroscope upgrades reach the US market through FDA 510(k) clearance against an existing predicate rather than the more demanding PMA route, and the electronic image records these systems generate fall under FDA controls for electronic records and signatures set out in 21 CFR Part 11. In the EU, the same instruments are classified as medical devices under EU MDR, and the bloc’s Regulation (EU) 2025/327 brings medical imaging into its data-sharing scope from March 2031, layering onto GDPR’s existing health-data safeguards and favoring instruments built for structured digital output over analog viewing.

Computer-aided detection software is moving from pilot use into routine endoscopic screening

The World Health Organization’s 11 June 2025 policy update doubled endorsed computer-aided detection products for imaging-based screening from four to eight, setting a market-access precedent diagnostic-imaging regulators are extending to endoscopic AI. First-of-kind CADe algorithms typically clear FDA review through the De Novo pathway before follow-on submissions proceed via 510(k). South Korea’s AI Framework Act, effective 22 January 2026, classifies such software as “high-impact,” formalizing oversight of its use. National health technology assessment bodies are beginning to weigh CADe reimbursement alongside the underlying endoscopy procedure code. Screening, the smallest gastroscopy application segment, stands to gain most as clinics add CADe modules for gastric cancer detection.

Upper GI endoscopy volume is migrating into ambulatory surgical centers

CMS’s Calendar Year 2026 outpatient and ambulatory surgical center final rule, effective 1 January 2026, added 560 procedures to the ASC Covered Procedures List and opened a three-year phase-out of the Inpatient Only list, with reimbursement keyed to the CPT/HCPCS codes assigned to each added procedure. Specialty clinics, the fastest-growing end-use setting for gastroscopy, and ambulatory surgical centers are absorbing volume once scheduled in hospital suites. Patient records generated at these lower-acuity sites still carry the same HIPAA handling obligations as hospital-based endoscopy. The shift is pulling equipment purchasing toward compact gastroscope configurations sized for same-day throughput.

Regional Analysis

North America accounted for 34.36% of the electronic gastroscope market in 2025, the highest stated regional share. Reimbursement policy is the region’s defining mechanism: CMS retired Noridian’s colon capsule endoscopy coverage determination, LCD L38826, on 11 September 2025 and folded coverage criteria into a single consolidated local policy billed under existing CPT and HCPCS endoscopy codes. Electronic gastroscopes reach the US market through the FDA’s 510(k) clearance pathway rather than the more demanding PMA route, since the devices typically qualify as moderate-risk modifications to a predicate scope. The United States, the region’s largest national market, is expanding at a 6.10% CAGR.

A 27.06% share placed Europe in second position among the three stated regions in 2025. Karl Storz SE & Co. KG, headquartered in Germany, anchors the region’s manufacturing base for rigid and flexible endoscopic systems, selling into hospitals that now procure under EU MDR conformity rules rather than the retired Medical Device Directive. Device reimbursement is decided by national HTA bodies rather than the EMA’s centralised procedure, which governs medicines, not endoscopic hardware. Germany leads national demand within the region, growing at a 5.20% CAGR through the forecast period.

Asia Pacific trailed North America by roughly four points, holding 30.24% of the 2025 market. India’s National Health Authority is rolling out a hospital-based clinical decision module across approximately 70,000 public and private facilities under the Ayushman Bharat Digital Mission, widening the installed hospital base that gastroscopy equipment sells into, while device import and registration in the country runs through CDSCO. India is growing at 5.80% and Japan at 5.10%.

Brazil, the region’s only named market in the fact set, is expanding at a 5.50% CAGR. Public hospital tenders concentrate purchasing decisions in the country, a procurement structure that rewards manufacturers able to clear ANVISA registration and bid at national tender scale over smaller distributors.

The Middle East and Africa’s electronic gastroscope demand tracks a wider build-out of hospital diagnostic capacity. Saudi Arabia’s Seha Virtual Hospital, recognised by Guinness World Records as the world’s largest virtual healthcare provider, connects more than 224 hospitals and logged over 16 million consultations in 2025, the clearest marker of hospital-based infrastructure scale in the Gulf.

Segment Analysis

By Application

• Diagnostic (largest) – Use of an electronic gastroscope to visually examine the esophagus, stomach, and duodenum to identify ulcers, inflammation, tumors, or other mucosal abnormalities

• Gastroesophageal Reflux Disease (GERD)
• Gastritis
• Peptic Ulcer Disease
• Barrett’s Esophagus
• Gastric Tumor/Cancer Detection
• Therapeutic (fastest-growing) – Application of a gastroscope to deliver treatments such as bleeding control, polyp removal, stricture dilation, or foreign object retrieval within the upper gastrointestinal tract

• Hemostasis (Bleeding Control)
• Polypectomy
• Stricture Dilation
• Foreign Body Removal
• Stent Placement
• Surgical – Use of a gastroscope to guide or perform minimally invasive procedures, such as endoscopic mucosal resection or submucosal dissection, without open incisions

• Endoscopic Submucosal Dissection (ESD)
• Endoscopic Mucosal Resection (EMR)
• Peroral Endoscopic Myotomy (POEM)
• Natural Orifice Transluminal Endoscopic Surgery (NOTES)
• Screening – Routine gastroscopic examination of asymptomatic or at-risk individuals to detect early signs of gastric disease, including precancerous lesions, before symptoms appear

• Gastric Cancer Screening
• Barrett’s Esophagus Screening
• Routine/Preventive Health Check-up

By End Use

• Hospitals (largest) – Large healthcare facilities where electronic gastroscopes are used by gastroenterologists for inpatient endoscopic diagnosis, surgery, and treatment of digestive tract disorders

• Public Hospitals
• Private Hospitals
• Ambulatory Surgical Centers – Standalone same-day care facilities that perform outpatient gastroscopy procedures such as screenings and minor interventions without overnight hospital admission

• Single-Specialty ASCs
• Multi-Specialty ASCs
• Specialty Clinics (fastest-growing) – Dedicated gastroenterology or digestive health practices that use electronic gastroscopes for routine diagnostic examinations and follow-up care outside a hospital setting

• Gastroenterology Clinics
• Diagnostic Centers

Hospitals led end-use demand in 2025, the largest of the three settings. Capital-intensive video processors, light sources and reprocessing infrastructure concentrate gastroscopy in facilities that can support inpatient case volume alongside complex therapeutic and surgical procedures such as endoscopic submucosal dissection, and inpatient billing runs through CMS reimbursement under CPT and HCPCS endoscopy codes that clinics and ambulatory centers must also meet before a procedure is covered. Specialty clinics are growing fastest, as routine diagnostic and screening gastroscopy shifts to dedicated gastroenterology practices and diagnostic centers outside the hospital setting, a lower-cost outpatient path for cases that do not need hospital-level surgical backup, and one that health technology assessment bodies outside the U.S. tend to favor when setting coverage terms.

By Product Type

• Flexible Gastroscopes (largest) – A gastroscope with a bendable insertion tube used to navigate the curves of the upper digestive tract for diagnostic and therapeutic endoscopy

• Diagnostic Gastroscopes
• Therapeutic Gastroscopes

• Single-Channel
• Double-Channel
• Ultra-thin/Transnasal Gastroscopes
• Rigid Gastroscopes (fastest-growing) – A gastroscope with a fixed, non-bending tube used for direct visualization and limited access procedures within the stomach cavity

• Fiber-optic Rigid Gastroscopes
• Rod-lens Rigid Gastroscopes
• Video Gastroscopes – A gastroscope fitted with a miniature digital camera at its tip that transmits real-time images of the gastrointestinal lining to an external monitor

• CCD Video Gastroscopes
• CMOS Video Gastroscopes
• High-Definition Video Gastroscopes

Flexible gastroscopes led the product-type segment in 2025. Their bendable insertion tube reaches the curves of the esophagus, stomach and duodenum without the constraints of a fixed-tube design, and the same platform covers diagnostic, therapeutic and screening use under a single FDA 510(k) or De Novo clearance in the U.S. and CE marking under the EU Medical Device Regulation in Europe, which makes it the standard purchase for hospital endoscopy suites. Rigid gastroscopes are expanding fastest among the three, from a smaller installed base, pulled by lower unit cost and use in limited-access procedures within the stomach cavity that do not require a full flexible video stack; in India, clearance through the CDSCO has supported this lower-cost category in price-sensitive procurement.

By Technology

• Optical Technology (largest) – Fiberoptic gastroscope system that transmits images through glass fiber bundles to an eyepiece for direct visual examination of the upper gastrointestinal tract

• Fiber-Optic Gastroscope
• Rigid Optical Gastroscope
• Digital Technology (fastest-growing) – Videoscope system using a CCD or CMOS image sensor at the tip to capture and display gastrointestinal images on an external monitor

• Video Gastroscope
• High-Definition Gastroscope
• Capsule Endoscope
• Wireless Technology – Gastroscope configuration that transmits captured images or video to a display or recording unit without a physical cable connection

• Wireless Capsule Gastroscope
• Bluetooth-Enabled Gastroscope

Optical technology led the technology axis in 2025, the installed base built on fiber-optic systems still in service across older endoscopy units. Digital technology, built on CCD and CMOS image sensors, is growing fastest as hospitals and clinics replace fiber-optic scopes with video gastroscopes for sharper mucosal visualization and easier image documentation, a shift that brings gastroscopy image archives under 21 CFR Part 11 electronic-record controls in the U.S. and under HIPAA and GDPR data-handling rules wherever those images are stored or transmitted. Wireless formats, including capsule-based systems, remain the smallest category but extend gastroscopy into settings that cannot support a tethered video stack, provided the image link itself meets the same patient-data protection standard.

By Patient Demographics

• Adults (largest) – Electronic gastroscopes used to examine the esophagus, stomach, and duodenum in patients from early adulthood through late middle age

• Young Adults
• Middle-Aged Adults
• Pediatrics – Electronic gastroscopes built with narrower-diameter insertion tubes and adapted controls for endoscopic examination of infants, children, and adolescents

• Neonates
• Infants
• Children
• Adolescents
• Geriatrics (fastest-growing) – Electronic gastroscopes used for upper gastrointestinal diagnosis and treatment in elderly patients, often alongside age-related comorbidities and frailty considerations

• Young-Old
• Middle-Old
• Oldest-Old

Country Growth Comparison

The country CAGRs span 1.0 percentage points, from United States at 6.1% to Japan at 5.1%.

Competitive Landscape

The electronic gastroscope market is fragmented: Olympus Corporation, Fujifilm Holdings Corporation and a wide field of specialists compete with no single company holding a majority position. Competition centers on clinical image quality and channel breadth: reprocessing and consumable lock-in tied to a given video processor platform, hospital and ambulatory surgical center contracting, and the depth of a company’s therapeutic accessory line for polypectomy, hemostasis and stricture dilation. Regulatory clearance status and installed base within existing endoscopy suites also weigh heavily, since replacing a processor platform means replacing the accessory ecosystem built around it.

The market is led by a group of established manufacturers: Olympus Corporation, Fujifilm Holdings Corporation, Pentax Medical and Hoya Corporation, all headquartered in Japan; Medtronic plc, Boston Scientific Corporation, Conmed Corporation and Stryker Corporation among the diversified device majors; Karl Storz SE & Co. KG in Germany; Ambu A/S in Denmark and Given Imaging Ltd in Israel as single-use and capsule endoscopy specialists; Shanghai AoHua Photoelectricity Endoscope Co., Ltd. as a regional Chinese manufacturer; and Crospon Ltd, an Irish GI diagnostic device specialist.

Strategic Outlook

The clearest whitespace through 2035 lies where therapeutic gastroscopy, the fastest-growing application, converges with the shift of routine procedures into specialty clinics and ambulatory surgical centers. Manufacturers that adapt hemostasis, polypectomy and dilation accessory lines to outpatient settings can capture volume moving out of the hospital, provided reimbursement coding follows the site-of-care shift.

By 2035, the product mix tilts further toward digital and video-based platforms as fiber-optic units are retired, while purchasing consolidates around processor ecosystems that lock in accessories and service contracts, favoring manufacturers with the broadest therapeutic and diagnostic accessory range.

Electronic Gastroscope Market Report Scope